AuthorisedTherapeutic exploratory (Phase II)Interventional

BASECOVID - Bevacizumab in post-acute sequelae of COVID-19 : Efficacy and Safety (Pilot Study)

This research, called BASECOVID, is a pilot study investigating a medication called Bevacizumab. It's for adult patients who are still experiencing breathlessness more than three months after their COVID-19 infection. The main goal is to see if taking Bevacizumab can improve a specific measure of lung function related to how well oxygen gets into the blood, by at least 10% within three months. Researchers will also look at whether the treatment helps with other long COVID symptoms like tiredness, and assess psychological well-being. They will monitor how safe the treatment is and record any side effects. This is a Phase II study, meaning it's an early step to see if the treatment works and is safe enough to study further.

At a glance

Status

Authorised

Phase

Therapeutic exploratory (Phase II)

Sponsor

Assistance Publique Hopitaux De Paris

Enrolment target

Start

24 Oct 2025

Adult patients with persistent dyspnea more than 3 months after acute COVID-19 infection.

What is this study about?

Many people who have had COVID-19 find that some symptoms, like breathlessness, can last for a long time – sometimes months or even longer. This can be really challenging and affect daily life. This study, called BASECOVID, is trying to find out if a particular medicine, Bevacizumab, could help these adult patients who are still struggling with breathlessness long after their initial COVID-19 illness. It's a pilot study, which means it’s an early step to see if this treatment shows promise.

The main thing researchers want to find out is whether Bevacizumab can improve how well patients' lungs transfer oxygen into their blood. They’ll be looking for an improvement of at least 10% in a measurement called 'DLCO' over three months. This is an important way to check lung function. Beyond that, the study will also track other symptoms that commonly affect people with long COVID, such as tiredness, as well as looking at how the treatment might affect mental well-being and daily activities.

Because this is a new use for this medicine in long COVID, it's really important to also understand its safety. Researchers will carefully record any side effects or health changes experienced by participants. The aim is to gather enough information to decide if Bevacizumab could be a helpful treatment for breathlessness after COVID-19 and if it should be studied in more detail in the future.

Key takeaways

This study is for adults with long-lasting breathlessness after COVID-19.
It tests a medicine called Bevacizumab to see if it improves breathing.
Researchers will also track other long COVID symptoms and the safety of the treatment.
Participation involves taking the study drug and attending assessments over seven months.
This is an early-stage study to learn if the treatment could be helpful.

Who may be eligible?

This study is looking for adults who have had COVID-19 and are still experiencing breathlessness. To be considered, your breathlessness must have lasted for more than three months since you first got sick with COVID-19.

There isn't an upper age limit, so adults of any age can be considered if they meet the other criteria. Both men and women are welcome to take part in this research.

It's important to remember that this is a specific study, so there will be other detailed medical checks to make sure the treatment is suitable and safe for you. Your doctor or the research team would discuss these with you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you an adult (18 years or older)?
Did you have COVID-19?
Have you been experiencing breathlessness for more than 3 months since your COVID-19 infection?
Are you able to commit to seven months of study visits and assessments?

Answer every question to see your result.

What does participation involve?

If you join this study, you would receive the study medication, Bevacizumab. Over the course of seven months, you would have several visits or assessments. These will include regular check-ups to monitor your general health and how you're feeling. You'll have lung function tests to see how well your lungs are working and to track changes in breathlessness. The research team will also ask you to complete questionnaires about your symptoms, including breathlessness, tiredness, sleep quality, and how these affect your daily life and mood.

You would also have blood tests at different points to look at specific health markers. Throughout the study, the team will closely monitor you for any side effects and record any hospital visits or medical consultations you might need. The total duration of your active participation, including follow-up, would be seven months.

Potential risks and benefits

Participating in a study like this means you would receive a new treatment for your symptoms that might not be available otherwise. There is a potential benefit that Bevacizumab could help improve your breathlessness and other long COVID symptoms, however, as this is a pilot study, we don't know for certain if it will be effective. All medications have potential side effects, and while the research team will closely monitor you, there's a possibility you might experience adverse reactions to Bevacizumab. You have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
France

Common questions

What is Bevacizumab?

Bevacizumab is a medication that targets specific proteins in the body. It is already used for other medical conditions, but this study is testing if it can help with long COVID symptoms like breathlessness.

What does 'Phase II trial' mean?

A Phase II trial is an early stage of research where doctors start testing a new treatment on a small group of people. The main goals are to see if the treatment works, how safe it is, and what the right dose might be.

What is 'DLCO'?

DLCO stands for 'Diffusing Capacity of the Lung for Carbon Monoxide'. It's a test that measures how well oxygen moves from your lungs into your bloodstream. If your DLCO is low, it suggests your lungs might not be working as efficiently as they should.

Will this study cure my long COVID?

This is a pilot study to see if a particular treatment (Bevacizumab) can help improve breathlessness. We don't know if it will 'cure' long COVID, but it aims to explore potential new ways to manage the symptoms. It's an important step in understanding the condition better.

How long will I be in the study if I participate?

If you join, your participation, including receiving the medication and follow-up assessments, will last for a total of seven months.